Heron Therapeutics to Present at the Bank of America Merrill Lynch 2014 Health Care Conference
REDWOOD CITY, Calif.--(BUSINESS WIRE)--May 1, 2014--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical
company, announced today that Barry Quart, Pharm.D., Chief Executive
Officer of Heron, will present at the Bank of America Merrill Lynch 2014
Health Care Conference on Wednesday, May 14, 2014 at 11:20 a.m. PT in
Las Vegas, NV.
A live webcast of this presentation will be available on the Company’s
website at www.herontx.com
in the Investors section. A replay of the presentation will be archived
on the site for 90 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (formerly A.P. Pharma, Inc.) is a specialty
pharmaceutical company developing products using its proprietary
Biochronomer™ polymer-based drug delivery platform. This drug delivery
platform is designed to improve the therapeutic profile of injectable
pharmaceuticals by converting them from products that must be injected
once or twice per day to products that need to be injected only once
every one or two weeks. The Company's lead product, SUSTOL™ (formerly
known as APF530), is being developed for the prevention of both acute-
and delayed-onset chemotherapy-induced nausea and vomiting.
In addition to SUSTOL, Heron is also utilizing its proprietary,
extended-release Biochronomer technology to develop other drugs designed
to extend the duration of action of known active ingredients to address
important unmet medical needs. In November 2013, the Company announced
movement into full development of the first of these new drug programs -
the Biochronomer extended release of an established local anesthetic for
the treatment of post-surgical pain. In recently completed,
post-surgical animal models of pain, the Company's drug candidates
demonstrated statistically significant pain relief for five days,
representing the potential to significantly reduce the need for opiates
post-surgery and the length of post-surgical hospital stays. Heron
expects to move its pain program into human clinical studies in mid-2014.
Forward Looking Statements
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements involve risks and uncertainties, including
uncertainties associated with the potential approval of SUSTOL™ and the
potential timing for such approval, if approved at all, as well as risks
and benefits relating to listing on the NASDAQ Capital Market, progress
in research and development programs, launch and acceptance of new
products and other risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. We caution
investors that forward-looking statements reflect our analysis only on
their stated date. We do not intend to update them except as required by
Source: Heron Therapeutics, Inc.
Heron Therapeutics, Inc.
Investor Relations Contact:
Stephen R. Davis, 650-366-2626
President and Chief Operating Officer